Scott & Selber Inc. Grows Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Scott & Selber Inc. increased its holdings in Illumina, Inc. (NASDAQ:ILMN) by 4.4% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,693 shares of the life sciences company’s stock after buying an additional 285 shares during the period. Scott & Selber Inc.’s holdings in Illumina were worth $2,464,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Broderick Brian C lifted its holdings in Illumina by 0.3% in the 2nd quarter. Broderick Brian C now owns 13,240 shares of the life sciences company’s stock valued at $4,874,000 after purchasing an additional 36 shares in the last quarter. Foresight Wealth Management LLC increased its stake in shares of Illumina by 4.2% during the 2nd quarter. Foresight Wealth Management LLC now owns 972 shares of the life sciences company’s stock valued at $358,000 after acquiring an additional 39 shares during the last quarter. Sage Capital Advisors llc increased its stake in shares of Illumina by 0.7% during the 1st quarter. Sage Capital Advisors llc now owns 5,887 shares of the life sciences company’s stock valued at $1,829,000 after acquiring an additional 40 shares during the last quarter. Sterling Investment Advisors Ltd. increased its stake in shares of Illumina by 2.0% during the 1st quarter. Sterling Investment Advisors Ltd. now owns 2,090 shares of the life sciences company’s stock valued at $649,000 after acquiring an additional 40 shares during the last quarter. Finally, Greenleaf Trust increased its stake in shares of Illumina by 0.6% during the 2nd quarter. Greenleaf Trust now owns 6,691 shares of the life sciences company’s stock valued at $2,463,000 after acquiring an additional 42 shares during the last quarter. Institutional investors and hedge funds own 90.95% of the company’s stock.

In other news, SVP Charles Dadswell sold 124 shares of the stock in a transaction that occurred on Monday, July 1st. The stock was sold at an average price of $371.29, for a total transaction of $46,039.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mostafa Ronaghi sold 10,000 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.49, for a total value of $3,054,900.00. Following the transaction, the senior vice president now owns 87,414 shares of the company’s stock, valued at $26,704,102.86. The disclosure for this sale can be found here. Insiders sold 60,458 shares of company stock valued at $19,582,518 in the last ninety days. 0.38% of the stock is owned by corporate insiders.

A number of research firms have recently commented on ILMN. Wolfe Research began coverage on shares of Illumina in a research note on Thursday, May 30th. They set an “outperform” rating for the company. Cowen dropped their target price on shares of Illumina from $380.00 to $320.00 and set an “outperform” rating for the company in a research report on Friday, July 12th. UBS Group increased their target price on shares of Illumina from $350.00 to $355.00 and gave the stock a “buy” rating in a research report on Tuesday, July 30th. Piper Jaffray Companies dropped their target price on shares of Illumina from $382.00 to $348.00 and set an “overweight” rating for the company in a research report on Tuesday, July 30th. Finally, BidaskClub downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 13th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $330.92.

ILMN traded up $4.60 on Tuesday, reaching $294.94. 33,298 shares of the company’s stock were exchanged, compared to its average volume of 1,381,672. The company’s 50 day simple moving average is $323.93. The company has a market capitalization of $43.22 billion, a P/E ratio of 51.56, a price-to-earnings-growth ratio of 2.74 and a beta of 1.10. Illumina, Inc. has a twelve month low of $268.62 and a twelve month high of $380.76. The company has a current ratio of 6.79, a quick ratio of 6.10 and a debt-to-equity ratio of 0.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, July 29th. The life sciences company reported $1.35 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.32 by $0.03. Illumina had a net margin of 27.56% and a return on equity of 21.73%. The company had revenue of $838.00 million during the quarter, compared to the consensus estimate of $835.12 million. During the same quarter last year, the company earned $1.43 earnings per share. Illumina’s revenue for the quarter was up 1.0% on a year-over-year basis. As a group, equities research analysts forecast that Illumina, Inc. will post 6.04 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Read More: Cash Flow Analysis in Stock Selection

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.